Of all cancer types, the use of targeted therapies was greatest in metastatic colorectal cancers, where EGFR (epidermal growth factor receptor) inhibitors (e.g., cetuximab) and anti-angiogenic agents (e.g., bevacizumab) are commonly used [30]. This evidence concerns the gene EGFR and metastatic colorectal cancer.